Stock Price & Analysis

ITCI stock is currently trading near its acquisition price of $132 by Johnson & Johnson, with limited upside expected. Given its strong performance in a defensive sector but overbought technical indicators, it may be wise to sell or hold.

The price prediction for ITCI stock in 2025 is $132. This target is based on the recent acquisition agreement with Johnson & Johnson, with analysts expecting the stock to trade closely around this price.

The S1 support level for ITCI Stock is $131.26 ,The R1 resistant level for ITCI Stock is $131.72.

As of the end of day on 2025-03-26, the price of ITCI Stock was $131.685.

The target price for ITCI Stock according to analyst rating is 130.83, with the highest price target at 132.00 and the lowest at 118.00. Analysts have a Moderate Buy rating on ITCI Stock overall.

The market cap of ITCI is $14.0B.

Analysis and Insights

Valuation Metrics:

ITCI's current valuation metrics suggest potential overvaluation. The stock's EV/EBITDA ratio of 12.65 and PS ratio of 7.73 are relatively high, indicating a premium price relative to its earnings and revenue.

Market Sentiment and Analyst Ratings:

ITCI has received a 72% rating from Validea's Quantitative Momentum Investor model, reflecting strong momentum. However, multiple analysts have downgraded the stock to Neutral or Hold, citing limited upside due to its pending acquisition by Johnson & Johnson.

Technical Analysis:

The stock's RSI of 85.25 indicates overbought conditions, while its price near the upper Bollinger Band suggests elevated valuations.

Conclusion:

ITCI appears overvalued due to high valuation multiples, analyst downgrades, and technical overbought signals. Investors should exercise caution.

Intra-Cellular Therapies, Inc. is a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders. The Company leverages intracellular approach to develop treatments for people living with complex psychiatric and neurologic diseases. The Company’s product, CAPLYTA (lumateperone), is an oral, once daily atypical antipsychotic approved in adults for the treatment of schizophrenia and the treatment of depressive episodes associated with bipolar I or II disorder (bipolar depression) as monotherapy and as adjunctive therapy with lithium or valproate. Its pipeline includes several product candidates in clinical development and additional product candidates in non-clinical testing, such as ITI-1284-ODT-SL program, Phosphodiesterase type I inhibitor (PDE1) program, ITI-333 program, and ITI-1500 Non-Hallucinogenic Psychedelic program. ITI-1284 is a deuterated form of lumateperone, a new chemical entity.

The price prediction for ITCI stock in 2030 is approximately $132. This forecast is based on the stock's current trading range near Johnson & Johnson's acquisition offer of $132 per share, with analysts expecting limited upside due to the pending takeover. Technical indicators and analyst downgrades to Hold also support this price level.

ITCI has a total of 610 employees.